To evaluate the perioperative, pathological, and oncological outcomes from surgeon-led pathological staging of pelvic lymph node (LN) metastases at the time of robot-assisted radical prostatectomy (RARP).
Patients and Methods
Over the 6-year period of 2006-2012, three distinct pelvic LN dissection (PLND) strategies were used in chronological order at a single cancer referral hospital. Strategies were characterised by both an omission of PLND (pNx) vs inclusion decision threshold, and standard vs extended templates for patients selected for PLND. The three cohorts included: (i) omission vs standard template (04/2006-10/ 2007), for dominant Gleason score 4-5 or a prostate-specific antigen (PSA) level of >10 ng/mL; (ii) omission/standard vs extended template (11/2007-12/2010 ), for dominant Gleason score 4-5, PSA level of >10 ng/mL, any single core >7 mm, or >3 ipsilateral positive cores; and (iii) extended template with minimal exceptions (01/2011-08/2012). Standard outcomes data compared included: Clavien-Dindo complication rates, LN metrics (yield, percentage positive), and biochemical recurrence (BCR). A novel metric comprised 'pNx regret': the rate of pNx patients upgraded/upstaged. Exploratory analyses included selection criteria for reduced PLND templates, i.e. low-yield subsets.
Results
Standard PLND yielded 8-10 LNs and a positive-LN yield of 2.2-6.2%. The addition of an extended PLND (E-PLND) significantly increased the yield to [14] [15] [16] [17] [18] [19] [20] LNs and the positive-LN yield to 17.4-18.4% (both P < 0.001). E-PLND had the highest impact on the percentage of positive LNs (%pN1) for high-risk disease (9.3 vs 32.8%, P = 0.002), modest for intermediate risk (4.2 vs 10.9%, P = 0.003), and minimal impact on low risk disease (4.1 vs 0%, P = 0.401). The combined strategies of setting a very low threshold for E-PLND and sending separate LN packets increased the LN yields (18 vs 24, P < 0.001), but did not significantly change the observed %pN1 rates by clinical risk group (P = 0.975). Efforts to reduce the need for E-PLND included omission by clinical criteria, but resulting in 'pNx regret' in 16-19% . A third of patients with unilateral disease and positive LNs were found to have contralateral disease. A subset of men with minimal biopsy volume Gleason score 4 + 3 had pN1 rates after E-PLND of three of 14 (21%) compared to minimal biopsy volume Gleason score 3 + 4 pN1 rates after E-PLND of 0 of 31. E-PLND takes about twice as long to perform but with no statistically significant difference in complications (5.0 vs 6.0%, P = 0.511). The 5-year BCR rates were higher for E-PLND, given the selection criteria, but not different for overall survival.
Introduction
A pelvic lymph node dissection (PLND) is a standard consideration for patients with clinically localised prostate cancer who have selected attempted curative treatment with radical prostatectomy (RP) [1] . The indications for PLND and the anatomical extent of the dissection are the two key decision points for the surgeon and remain controversial, although there is increasing agreement that the rates of lymph node (LN) metastases (pN1) are very low in low-grade/low-volume disease [2, 3] . The developments of minimally invasive techniques in RP have, in turn, required a parallel adoption of the appropriate technique of PLND [4] . The pathological LN assessment is part of the TNM staging system, and the finding of tumour in ≥1 LN (s) is one of the more significant predictors of biochemical recurrent disease [5] . Therefore, in patients at risk of pN1, an accurate PLND needs to be performed to identify the best adjuvant/salvage treatments and improve staging accuracy, even in the current era where the therapeutic value is uncertain [1] .
Prior to 2002, it was fairly established that the obturator fossa was the most productive technique of PLND, and became the basis of many prediction tables and nomograms to guide safe omission (pNx) in lower risk cases [6, 7] . The template concepts were challenged by the publication by Bader et al. [8] from Bern, Switzerland in 2002. The extended PLND (E-PLND) template was described as obturator + medial external iliac artery + external iliac vein + hypogastric nodal regions. The number of LNs increases, but the noteworthy findings were that 58% of involved LNs were in the hypogastric zone -19% of uniquely positive LNs [8] . In 2011, we published our initial experience using a robotic technique for E-PLND and found that the yield of LNs and positive LNs increased significantly. However, there was the impression of slightly higher complications, a very distinct increase in operative time, and a yield of percentage of positive LNs (%pN1) that was remarkable (just under 40%) in high-risk disease, whilst considerably less yield for the increased effort amongst intermediate-(9%) and low-risk (<3%) disease [4] . We also noted and questioned the significance of the~17% of patients with pNx disease that had upgrading/upstaging at RP, to the extent that we would have retrospectively wished we had included a PLND -a term we will call 'pNx regret'.
In the present study, we analyse our chronology of changes in PLND strategy and resulting impact on LN yield, pN1 stage, and oncological outcomes. As secondary endpoints, we examined the differences in operative times, length of hospital stay (LOS), and PLND-related complications for standard PLND (S-PLND) vs E-PLND.
Patients and Methods
The study is a prospective, comparative, non-randomised cohorts study (Level of Evidence 2b for a diagnostic study [9] ) involving two surgeons from a single tertiary care oncology focused institution. Institutional Review Board approval was obtained from The MD Anderson Cancer Center under the data review 'front-door' consent with waiver of individual consent policy: protocol DR 10-0554.
All included patients underwent robot-assisted RP (RARP) from April 2006 to August 2012. Study surgeons had similar experiences in laparoscopic RP (>200 cases each) before the study. The surgeons shared the same technique, with the intent to produce equivalent LN templates and documentation. Cohorts were consecutive during the study era with the exclusion of 38 patients due to a lack of 'frontdoor' consent, clinical N1 status, and pT0 status. Of note, patients underwent guidelines-based metastatic imaging evaluations, i.e. bone and/or CT abdomen/pelvis, for highgrade biopsies and/or a PSA level of >15 ng/mL. Therefore, low-risk and many intermediate-risk patients were not imaged. Many patients had MRI for nerve-sparing planning or active surveillance eligibility with comment on LNs. The present study excluded cN1 patients and pre-dated any modern (prostate-specific membrane antigen [PSMA], C-11, etc.) positron emission tomography (PET) imaging.
Data collection for perioperative outcomes was prospectively recorded. Follow-up endpoints (disease-free status, complications, and subsequent therapies) were derived from patient electronic medical records and supplemented with follow-up telephone interviews for patients discharged to local care. Prostate cancer risk groupings used the National Comprehensive Cancer Network (NCCN) Guidelines criteria [10] . All outside prostate biopsy specimens were re-reviewed at the institution by a core of genitourinary pathologists and the in-house results used for risk grouping. RP specimens and LN specimens were evaluated by a single genitourinary pathologist. Perioperative data focused on total LN counts per side, and the %pN1. Because of the observation that some patients selected for no PLND are subsequently found to have higher risk pathology, we proposed the novel term 'pNX regret', as a patient selected for no PLND who has RP specimen stage T3 and/or Gleason score ≥4 + 3. This simple term denotes patients for whom we regret omitting a PLND. Complications related to a PLND, such as lymphocoele or pelvic abscess, neuropraxia, deep vein thrombosis, prolonged lymphatic drainage, and lower extremity/scrotal oedema, were recorded and graded according to the Clavien-Dindo system [11] . The amount of time (in minutes) to perform the PLND was recorded during each case as part of a training programme. In addition, the LOS was calculated for each patient.
The overall cohort of 1 590 patients was divided chronologically into comparative sub-cohorts that specified the techniques of PLND available, selection criteria, and comparative outcomes.
Group 1, S-PLND, April 2006 to October 2007
The standard template was a meticulous dissection of the obturator fossa [4] , and the selection criteria designed to predict pN1 staging from this technique were: dominant Gleason pattern 4-5, or PSA level of >10 ng/mL [12] . During this era, one surgeon performed exclusively robotic, whilst the other was utilising laparoscopic initially and transitioning to robotic. Moving forward, all surgeries were performed robotically.
Group 2, E-PLND with selective criteria, November 2007 to December 2010
The E-PLND technique started in November 2007 as previously reported [4] . The selection criteria used our inhouse derived criteria for predicting pT3 stage: primary Gleason score 4-5 pattern, >3 ipsilateral positive cores, any single biopsy core >7 mm, or a PSA level of >10 ng/mL [13] . Noteworthy for this time period: European Association of Urology guidelines [1] recognised the value of an E-PLND in high-risk disease, whereas the AUA [14] did not have a standard guidelines statement regarding PLND.
Group 3, E-PLND with non-selective criteria, January 2011 to August 2012
Analysis of cohorts 1 and 2 in 2010 showed higher LN yields and % pN1 staging from the E-PLND [4] . It also showed a 17% risk of upgrading and/or upstaging amongst patients selected for no PLND -'pNx regret'. Therefore, from January 2011 to August 2012, we attempted E-PLND in most patients, unless there were concerns for prolonged operative time/co-morbidity, or near-active surveillance criteria risk group patients who selected surgery anyway. Patients not undergoing E-PLND either underwent S-PLND or none (pNx).
Up until January 2012, all S-PLND and E-PLND LN packets were submitted as two specimens -left and right pelvic LNs.
From January 2012 to August 2012, a novel product called the 'Anchor Tissue Retrieval System' (Addison, IL, USA) was used that allows multiple extraction of small specimens from the same bag. This allowed the latter cohort of patients to have the LNs submitted as four specimens -right and left obturator/external iliac, and right and left hypogastric.
Additional exploratory cohorts were defined to evaluate clinical predictors that would lessen the need for full bilateral E-PLND templates. The question of disease laterality was addressed for patients with positive LNs from E-PLND templates who had unilateral dominant tumour or biopsies. The question of minimal volume Gleason score 7 was addressed amongst patients with 1-2 positive cores, length <5 mm, PSA level of <10 ng/mL, and multi-parametric MRI consistent with organ-confined disease.
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS â ) version 22.0 software program for Windows (SPPS Inc., Chicago, IL, USA). Summary statistics were used to describe the three study groups. Kruskal-Wallis equality-of-populations rank test and Pearson's chi-squared test (or Fisher's exact test), and oneway ANOVA were used to compare the three study groups. An a of 0.05 was used as the significance level for all the comparisons.
Results
The series of 1 590 RARP patients were divided into the three chronological cohorts: Group 1, contained 351 patients; Group 2, contained 801; and Group 3, contained 438. Tables 2 and 3 detail the results of groups 1-3 for perioperative outcomes and pathological staging. The highlights are as follows:
• In Group 1, 50% were pNx and the remaining had a S-PLND, with a median LN yield of 8 and pN1 rate of 3%. By risk group, the rate of pN1 was 11.1, 5.4, and 7.9% for low-, intermediate-, and high-risk disease, respectively.
• In Group 2, 44% were pNx, 8% had a S-PLND, and 49%
had an E-PLND. Table 2 shows the increase in median LN yield for E-PLND from 9 to 14, and Table 3 shows the % pN1 increase from 5 to 17%. By risk group, the rate of pN1 was 5, 10, and 32% for low-, intermediate-, and highrisk disease, respectively.
• In Group 3, 6% were pNx, 21% had a S-PLND, and 73%
had an E-PLND. Table 2 shows the increase in median LN yield for E-PLND from 10 to 20, and Table 3 shows the % pN1 increase from 2 to 18%. By risk group, the rate of pN1 was 3, 8, and 33% for low-, intermediate-, and highrisk disease, respectively. Exploratory Analyses: can we Perform less than a Bilateral E-PLND?
The feasibility of PLND omission is carefully charted in this chronological series. Groups 1 and 2 used published criteria, whilst Group 3 lowered the threshold further. For Group 1, 31 (18%) of 173 pNx cases with biopsy Gleason scores of ≤3 + 4 and cT1c-cT2 had RP Gleason scores of ≥4 + 3 and/or pT3 -a concept of 'pNx regret' when final pathology, if known, would have indicated a PLND. In Group 2, the rate of 'pNx regret' was 54 (16%) of 340 patients. In Group 3, designed to test the consequences of performing more E-PLND, the rate of 'pNx regret' was five (19%) of 26 patients -non-significant comparisons (P =0.791).
The feasibility of PLND omission was then examined in intermediate-risk disease using the predictors of low-volume biopsies, PSA level of <10 ng/mL, and an MRI consistent with organ-confined disease. These criteria matched 31 (11%) of 284 E-PLNDs performed for biopsy Gleason score 3 + 4 and 14 (7%) of 213 E-PLNDs for biopsy Gleason score 4 + 3. In these cohorts, the pN1 rate was 0% for Gleason score 3 + 4 and 21% (3 of 14) for 4 + 3.
The feasibility of a unilateral E-PLND (with contralateral omission or standard) was examined in the E-PLND cohorts. In a sub-cohort of 23 patients with pN1 disease and strictly unilateral positive biopsies: six (26%) had contralateral positive LNs. Our genitourinary pathologist then examined the RP specimens from pN1 patients with E-PLND templates and identified 13 patients with exclusively unilateral dominant disease and 19 with predominately unilateral dominant disease. The rates of contralateral positive LNs were three (23%) and seven (37%), respectively.
PLND Outcome Measures, Complications, Oncological Impact
The median operative time to perform a S-PLND (n = 99) and an E-PLND (n = 563) was 20 and 37 min, respectively (P < 0.001) (data from cases where staff recorded their times as part of training comparisons). Table 2 compares the procedure times and LOS. The PLND-related complications are listed in Table 5 . The overall complication rate was 3.8%. In Group 1, there were a total of five (1.4%) complications, and 16 (2%) and 37 (8.5%) in groups 2 and 3, respectively (P < 0.001). There was no significant difference in the number of PLND-related complications between the S-PLND and E-PLND cohorts (5.0 vs 6.0%, P = 0.511). The two most common complications were neuropraxia (e.g. obturator palsy; 23 cases, 1.4%) and symptomatic or infected lymphocoele requiring drainage (17 cases, 1.1%). All of the lymphocoele complications were classified as Clavien-Dindo grade IIIa, except one that required surgical intervention, and therefore, was Grade IIIb. All neuropraxia, lower extremity/ scrotal oedema, and prolonged lymphatic drainage complications were classified as Grade I, and deep vein thrombosis complications were classified as Grade II (Table 5 ).
The 5-year biochemical recurrence (BCR)-free survival rate was 94.4, 88.8, and 74.1% for all patients selected for none (pNx), S-PLND, and E-PLND, respectively (P < 0.001; E-PLND vs pNx or S-PLND and shown in Fig. 1A) . By cohort groups, 5-year BCR-free survival was 90.9, 85.4, and 62.5% for groups 1, 2, and 3, respectively (P < 0.001; Fig. 2A ). As noted, patient biopsy, PSA level, and clinical stage findings were used to make these selections, and BCRfree rates were expected to be different. Therefore, we looked exclusively at pN1 patients and 5-year BCR-free survival: 55% for S-PLND and 33% for E-PLND cases (P = 0.042).
No significant difference was detected between S-PLND and E-PLND for overall survival. The 5-year overall survival was 96.7, 97.7, and 96.8% for none, S-PLND, and E-PLND, respectively for all groups (P = 0.933, Fig. 1B) . By cohort analysis, there was no significant difference in 5-year overall survival: 97.4, 96.1, and 97.8% for groups 1, 2, and 3, respectively (P = 0.350, Fig. 2B ).
Prostate-specific antigen level, clinical and pathological stage and grade, and neoadjuvant treatment rate were significantly higher in the E-PLND group. Therefore, one-to-one propensity score matching [15] was performed to compare S-PLND and E-PLND effectively (Table 6 ). Despite LN yield (8 vs 16, P < 0.001) and %pN1 (5 vs 13%, P = 0.001) being higher for E-PLND, there was no difference between S-PLND and E-PLND in terms of BCR-free survival (P = 0.272, Fig. 3A ) and overall survival rates (P = 0.547, Fig. 3B ).
Discussion
Our present findings confirm previous studies showing increased LN yield and %pN1 from E-PLND templates [8, [16] [17] [18] [19] [20] [21] [22] . Our previous technical reports [4, 23] demonstrate the 5-year overall survival was 96.7%, 97.7%, and 96.8% for none, S-PLND and E-PLND, respectively (P =0.986). robotic version of how to add a meticulous hypogastric artery template and improved obturator space and external iliac templates. The present study links the technique to the impact of patient selection and risk-group analysis. In addition to the impact of E-PLND on overall LN counts and %pN1 yield, our conclusions and unmet needs assessments from our present data are summarised with relevant literature comment:
• E-PLND LN yield increased over time from 14 (Group 2) to 20 (Group 3), indicating a learning curve improvement. Separating specimens into multiple zones appears to increase LN counts but not positive-LN counts. Eden et al. [22] observed an increase in LN yield from 9 to 20 after 500 laparoscopic (non-robotic) procedures.
• E-PLND %pN1 impact is 2-3 times in intermediate-risk and 3-4 times in high-risk disease. There was no impact in low-risk disease. Therefore, we perform E-PLND in all high-risk cases, and very few in low-risk cases. Kim et al. [16] made a similar observation in intermediate-/high-risk patients with~2-times the LN yield (12-21, P < 0.001) and 2.5-times %pN1 (5-12.1%, P = 0.033). Although not a 'direct' therapeutic effect, patients found to have pN1 could be managed with early androgen deprivation according to Level 1 Evidence, i.e. the Messing et al. [24] study. Patients with 1-2 LNs may have durable cancer-specific survival [25] [26] [27] [28] [29] [30] and/or be selected for clinical trials. Patients with E-PLND and pN0 might be better staged and have better results with adjuvant/salvage external beam radiation therapy for high-risk local disease findings (pT3a/b, positive margins).
• pN1 can crossover despite unilateral disease in about a third of cases and is therefore not a good method of decreasing the need for E-PLND on one side.
• A small fraction of patients with Gleason score 3 + 4 with low-volume biopsies and organ-confined MRI may be suitable for E-PLND omission. All of the low-risk patients with pN1 had upgrading/upstaging of their primary (Table 3) , consistent with the biology that pathological Gleason score 3 + 3 does not metastasise.
• 'pNx regret' is not a previously explored theme, but is probably a significant factor in surgeons' minds when selecting patients and experiencing the outcomes. The rate of 'pNx regret' did not seem to change by lowering the threshold of E-PLND indication. Therefore, it may be a 5-year BCR-free survival was 90.9%, 85.4%, and 62.5% for group 1, group 2, and group 3, respectively (P <0.001).
5-year overall survival was 97.4%, 96.1%, and 97.8% for group 1, group 2, and group 3, respectively (P = 0.400). • PLND is not without expense, time, and complications.
The operative time is nearly doubled for E-PLND; however, we did not observe a difference in complications -3.8% overall. In the USA circumstance, it is noteworthy that the procedure code is no different for extended templates compared to standard, despite the impact on pathological staging and possible management decisions. PLND-related complications range from 4.1 to 19.8% [16, 32, 33] , with lymphocoele the most common [32, 34] .
• Not a primary aim of the present study, but it is noteworthy that the chronology of cases selected for RARP is measurably moving away from low risk. Consequently, the rates of pT3 disease and positive surgical margins are increasing. For the whole series, the rate of pT2 positive margins was 7.3% (no temporal trend, data not shown).
• [42] . We can only conclude, therefore, that the therapeutic value of E-PLND can only be determined with a randomised study design. A concept trial might randomise an E-PLND candidate patient between E-PLND and pNx, and first measure the impact on BCR. As a second stage, pNx patients with BCR would undergo salvage E-PLND to measure the effects.
Our present study has limitations related to its lack of a randomised design, single institution, and involvement only by surgeons with significant past experience in minimally invasive RP. Although we have collected patient-reported functional outcomes in the clinic and for specific protocols, this cohort did not have a funded effort to collect them on a large enough scale to comment. This is a point of future study, as Sagalovich et al. [43] reported an adverse effect of E-PLND on potency. Our present study does not emphasise a particular learning curve for E-PLND, but we observe it to be as difficult to learn as the RP. Therefore, our present results may not be rapidly generalisable. Furthermore, we believe that the present study and any other on the topic are limited by difficulties in objectively defining the quality of an E-PLND. In a related model of applying E-PLND to bladder cancer, we found significant LN counts in full robotic PLND and eight zone specimen submission [44] . A second PLND by an open surgeon through the access created for open urinary diversion showed that more LNs could be retrieved with more effort, even if none were positive in this small series. Indeed, the senior author visited the Bern site [8] after completion of this cohort of patients, and discovered yet additional areas of LN retrieval in the triangular space of the origin of the external and internal iliac arteries and lateral from this point to the side wall and then down to the very proximal insertion of the obturator nerve into the sacrum. Additional LNs can be retrieved in the medial branches of the hypogastric artery in what can easily be ignored as perivesical fat. Some of this tissue joins the 'anterior fat' that some surgeons have reported as containing a few LNs and occasional pN1 [45] . Therefore, E-PLND is not always 'complete' PLND and performance of the latter could easily turn into a 2-h procedure and perhaps additional co-morbidity.
Conclusions
The E-PLND is well described in technique and can be matched with a robot-assisted technique without change in the complication rate. The effects of increased LN yield and positive-LN yield may have disease management advantages for select intermediate-(i.e. high volume Gleason score 3 + 4 or 4 + 3) and all high-risk patients, although therapeutic benefit measurement will require a randomised design. The time to complete the extended template is approximately double and when indicated should be a full bilateral template.
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